[go: up one dir, main page]

PT658118E - Vacinas contra neisseria meningitidis do grupo c - Google Patents

Vacinas contra neisseria meningitidis do grupo c

Info

Publication number
PT658118E
PT658118E PT93921251T PT93921251T PT658118E PT 658118 E PT658118 E PT 658118E PT 93921251 T PT93921251 T PT 93921251T PT 93921251 T PT93921251 T PT 93921251T PT 658118 E PT658118 E PT 658118E
Authority
PT
Portugal
Prior art keywords
gcmp
group
conjugate
modified
neisseria meningitidis
Prior art date
Application number
PT93921251T
Other languages
English (en)
Inventor
Harold Jennings
Joseph Y Tai
Francis Michon
Lucjan J J Hronowski
Sharon Mates
Original Assignee
Baxter Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/938,367 external-priority patent/US5425946A/en
Application filed by Baxter Healthcare Sa filed Critical Baxter Healthcare Sa
Publication of PT658118E publication Critical patent/PT658118E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
PT93921251T 1992-08-31 1993-08-30 Vacinas contra neisseria meningitidis do grupo c PT658118E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/938,367 US5425946A (en) 1992-08-31 1992-08-31 Vaccines against group C Neisseria meningitidis
US6450193A 1993-05-19 1993-05-19

Publications (1)

Publication Number Publication Date
PT658118E true PT658118E (pt) 2002-05-31

Family

ID=26744584

Family Applications (1)

Application Number Title Priority Date Filing Date
PT93921251T PT658118E (pt) 1992-08-31 1993-08-30 Vacinas contra neisseria meningitidis do grupo c

Country Status (12)

Country Link
EP (1) EP0658118B1 (pt)
JP (2) JP4097691B2 (pt)
AT (1) ATE212233T1 (pt)
AU (1) AU4841693A (pt)
CA (1) CA2142981C (pt)
DE (1) DE69331495T2 (pt)
DK (1) DK0658118T3 (pt)
ES (1) ES2171418T3 (pt)
NO (1) NO323616B1 (pt)
PL (1) PL175595B1 (pt)
PT (1) PT658118E (pt)
WO (1) WO1994005325A1 (pt)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780606A (en) * 1995-06-07 1998-07-14 Connaught Laboratories Limited Neisseria meningitidis capsular polysaccharide conjugates
GB9713156D0 (en) * 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
WO1998058670A1 (en) * 1997-06-24 1998-12-30 Chiron Corporation Methods of immunizing adults using anti-meningococcal vaccine compositions
US7749511B2 (en) 2000-04-18 2010-07-06 Endobiologics, Incorporated Anti-sepsis conjugate vaccine
WO2001078787A2 (en) 2000-04-18 2001-10-25 Endobiologics, Incorporated Lipopolysaccharide-conjugate vaccine for sepsis treatment
DK1355673T3 (da) * 2001-01-23 2012-09-17 Sanofi Pasteur Inc Multivalent meningococvaccine bestående af et polysaccharid/proteinkonjugat
BRPI0411815A (pt) * 2003-06-23 2006-08-08 Baxter Int vacinas contra neisseria meningitidis do tipo y e suas combinações meningocócicas
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
EP1961426B1 (en) 2003-10-02 2011-04-27 Novartis Vaccines and Diagnostics S.r.l. Combined meningitis vaccines
GB0406013D0 (en) 2004-03-17 2004-04-21 Chiron Srl Analysis of saccharide vaccines without interference
EP2272531A3 (en) 2004-04-30 2011-04-13 Novartis Vaccines and Diagnostics S.r.l. Integration of meningococcal conjugate vaccination
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
ES2670231T3 (es) 2006-03-22 2018-05-29 Glaxosmithkline Biologicals S.A. Regímenes para inmunización con conjugados meningocócicos
GB0605757D0 (en) 2006-03-22 2006-05-03 Chiron Srl Separation of conjugated and unconjugated components
IN2009KN04098A (pt) 2007-06-04 2015-08-28 Novartis Ag
PT2200642E (pt) 2007-10-19 2012-05-30 Novartis Ag Formulações de vacinas meningocócicas
GB0822633D0 (en) 2008-12-11 2009-01-21 Novartis Ag Formulation
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
EP2367568A2 (en) 2008-12-17 2011-09-28 Novartis AG Meningococcal vaccines including hemoglobin receptor
MX2011006756A (es) * 2008-12-22 2011-10-06 Novartis Vaccines & Diagnostic Prueba de bacteremia de proteccion pasica ex-vivo.
CA2756522C (en) 2009-03-24 2018-06-26 Novartis Ag Adjuvanting meningococcal factor h binding protein
NZ595291A (en) 2009-03-24 2013-08-30 Novartis Ag Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
US10478483B2 (en) 2010-06-25 2019-11-19 Glaxosmithkline Biologicals Sa Combinations of meningococcal factor H binding proteins
CA2828844C (en) 2011-03-02 2020-07-14 Novartis Ag Combination vaccines with lower doses of antigen and/or adjuvant
US9149541B2 (en) 2011-07-08 2015-10-06 Novartis Ag Tyrosine ligation process
AU2012335208B2 (en) 2011-11-07 2017-08-31 Glaxosmithkline Biologicals S.A. Carrier molecule comprising a spr0096 and a spr2021 antigen
AU2011384634A1 (en) 2011-12-29 2014-06-19 Novartis Ag Adjuvanted combinations of meningococcal factor H binding proteins
JP2015509963A (ja) 2012-03-08 2015-04-02 ノバルティス アーゲー Ｔｌｒ４アゴニストを含む混合ワクチン
CN104602705A (zh) 2012-09-06 2015-05-06 诺华股份有限公司 血清组b脑膜炎球菌和d/t/p的联合疫苗
WO2014095771A1 (en) 2012-12-18 2014-06-26 Novartis Ag Conjugates for protecting against diphtheria and/or tetanus
EP3613755A1 (en) 2013-07-11 2020-02-26 Novartis AG Lysine-specific chemoenzymatic protein modifications using microbial transglutaminase
MY186874A (en) * 2014-02-25 2021-08-26 Msd Wellcome Trust Hilleman Laboratories Pvt Ltd A novel downstream process for purifying polysaccharides
US12109259B2 (en) 2016-09-02 2024-10-08 Glaxosmithkline Biologicals Sa Vaccines for Neisseria gonorrhoeae
LT3506935T (lt) * 2016-09-02 2024-04-25 Sanofi Pasteur, Inc. Vakcina nuo neisseria meningitidis

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5097020A (en) * 1983-07-05 1992-03-17 The University Of Rochester Immunogenic conjugates
FR2682388B1 (fr) * 1991-10-10 1995-06-09 Pasteur Merieux Serums Vacc Procede de preparation d'un oligoside par depolymerisation d'un polyoside issu d'un agent pathogene, oligoside ainsi obtenu et son utilisation notamment comme agent vaccinal.

Also Published As

Publication number Publication date
CA2142981A1 (en) 1994-03-17
CA2142981C (en) 2007-10-23
AU4841693A (en) 1994-03-29
ES2171418T3 (es) 2002-09-16
PL307745A1 (en) 1995-06-12
JP2008044955A (ja) 2008-02-28
NO950739D0 (no) 1995-02-27
DE69331495D1 (de) 2002-03-14
PL175595B1 (pl) 1999-01-29
ATE212233T1 (de) 2002-02-15
WO1994005325A1 (en) 1994-03-17
DK0658118T3 (da) 2002-05-06
EP0658118B1 (en) 2002-01-23
JPH08500607A (ja) 1996-01-23
NO950739L (no) 1995-04-26
EP0658118A4 (en) 1995-09-13
NO323616B1 (no) 2007-06-18
EP0658118A1 (en) 1995-06-21
DE69331495T2 (de) 2002-10-31
JP4097691B2 (ja) 2008-06-11

Similar Documents

Publication Publication Date Title
PT658118E (pt) Vacinas contra neisseria meningitidis do grupo c
Schneerson et al. Serum antibody responses of juvenile and infant rhesus monkeys injected with Haemophilus influenzae type b and pneumococcus type 6A capsular polysaccharide-protein conjugates
Schneerson et al. Preparation, characterization, and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates.
ATE287947T1 (de) Orale immunisierung durch verwendung von transgenen pflanzen
ES8707861A1 (es) Un metodo para preparar un conjugado inmunogeno
RU2009134033A (ru) Жидкие вакцины для множественных серогрупп менингококков
ATE529130T1 (de) Trockenformulierung für transkutane immunisierung
DK0778781T3 (da) Pneumokok-polysaccharid-rekombinant pneumolysin-konjugat-vacciner til immunisering mod pneumokokinfektioner
NO306905B1 (no) Oligosakkarid avledet fra antigent polysakkarid erholdt fra et patogen
YU24391A (sh) Poboljšana meningokokna polisaharid kon-jugovana vakcina
BR9106748A (pt) Vacina de hyopneumomiae micoplasma inativado e metodo de seu uso
ES8608883A1 (es) Procedimiento de preparacion de un conjugado de muramilpeptido y de un hapteno o fragmento haptenico de bajo peso molecular.
DK0994721T3 (da) Nervevækstfaktor som vaccineadjuvans
NZ309713A (en) Oligosaccharides of S pneumoniae serotype 8 and their use in a vaccine
DK341679A (da) Vaccine mod streptokokker og fremgangsmaade til fremstilling deraf
IL107387A (en) Combination pediatric vaccine with enhanced immunogenicity of each vaccine component
Eskola et al. Experience in Finland with Haemophilus influenzae type b vaccines
Somani et al. Reimmunization after allogeneic bone marrow transplantation
ROBBINS et al. Haemophilus influenzae type b: the search for a vaccine
NO913131L (no) Immunogene konjugater av ikke-toksisk oligosakkarid fra bordetella pertussis lipoolysakkarid.
Frobisher Jr et al. Further studies on the immunization of rabbits to toxigenic Corynebacterium diphtheriae by injections of nontoxigenic diphtheria bacilli
DK0542895T3 (da) Krydsreaktiv influenza A immunisering
SHAMS et al. The effect of conjugation on immunogenicity and potency of protein carriers of polyribosylribitol phosphate (PRP) conjugated vaccines in the mouse model
MÄKELÄ et al. Vaccines for Haemophilus influenzae type b as models for an otitis vaccine
Guo et al. Studies on meningococcal polysaccharide-tetanus toxoid conjugates.